Synonym
Dirucotide acetate; SF 328; SF-328; SF328
IUPAC/Chemical Name
L-Threonine, L-alpha-aspartyl-L-alpha-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-, tetraacetate (salt)
InChi Key
AGWHZYPHHINWPT-WPDHDECSSA-N
InChi Code
AGWHZYPHHINWPT-WPDHDECSSA-N
SMILES Code
C[C@@H](O)[C@@H](C(O)=O)NC([C@H](CCCNC(N)=N)NC([C@H]1N(C([C@H]([C@H](O)C)NC([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=CC=C3)NC([C@H](CC4=CNC=N4)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H]5N(C([C@H](CC(N)=O)NC([C@H](CCC(O)=O)NC([C@H](CC(O)=O)N)=O)=O)=O)CCC5)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
2,253.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Boudesocque L, Forni L, Martinez A, Nuzillard JM, Giraud M, Renault JH. Purification of dirucotide, a synthetic 17-aminoacid peptide, by ion exchange centrifugal partition chromatography. J Chromatogr A. 2017 Sep 1;1513:78-83. doi: 10.1016/j.chroma.2017.07.003. Epub 2017 Jul 15. PMID: 28739271.
2: Deraos G, Kritsi E, Matsoukas MT, Christopoulou K, Kalbacher H, Zoumpoulakis P, Apostolopoulos V, Matsoukas J. Design of Linear and Cyclic Mutant Analogues of Dirucotide Peptide (MBP82⁻98) against Multiple Sclerosis: Conformational and Binding Studies to MHC Class II. Brain Sci. 2018 Dec 4;8(12):213. doi: 10.3390/brainsci8120213. PMID: 30518150; PMCID: PMC6316436.
3: Molecule of the month. Dirucotide. Drug News Perspect. 2008 Dec;21(10):572. PMID: 19221637.
4: Fontoura P, Garren H. Multiple sclerosis therapies: molecular mechanisms and future. Results Probl Cell Differ. 2010;51:259-85. doi: 10.1007/400_2010_36. PMID: 20838962.
5: Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5. PMID: 21975206.
6: Loo EW, Krantz MJ, Agrawal B. High dose antigen treatment with a peptide epitope of myelin basic protein modulates T cells in multiple sclerosis patients. Cell Immunol. 2012 Nov;280(1):10-5. doi: 10.1016/j.cellimm.2012.11.004. Epub 2012 Nov 27. PMID: 23246830.
7: Darlington C. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis. Curr Opin Mol Ther. 2007 Aug;9(4):398-402. PMID: 17694453.
